{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:17:00Z","timestamp":1774084620878,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jiac.2015.04.006","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T08:01:48Z","timestamp":1430553708000},"page":"551-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime\u2013avibactam in healthy Japanese volunteers"],"prefix":"10.1016","volume":"21","author":[{"given":"Nobumitsu","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timi","family":"Edeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Learoyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Ren\u00e9","family":"Bouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shampa","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2015.04.006_bib1","first-page":"114","article-title":"Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region","volume":"63","author":"Hsueh","year":"2011","journal-title":"J\u00a0Infect"},{"issue":"Suppl","key":"10.1016\/j.jiac.2015.04.006_bib2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0924-8579(12)70004-3","article-title":"In\u00a0vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"40","author":"Liu","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl","key":"10.1016\/j.jiac.2015.04.006_bib3","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0924-8579(12)70008-0","article-title":"Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009\u20132010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"40","author":"Lu","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2015.04.006_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajic.2011.05.020","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004\u20132009","volume":"40","author":"Rosenthal","year":"2012","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jiac.2015.04.006_bib5","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"Sheng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib6","first-page":"15","article-title":"Sensitivity surveillance of Pseudomonas aeruginosa isolates for several antibacterial agents in Gifu and Aichi prefecture (2008)","volume":"65","author":"Fujiwara","year":"2012","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2015.04.006_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2012.06.011","article-title":"Molecular characteristics of extended-spectrum b-lactamase-producing Escherichia coli in Japan: emergence of CTX-M-15-producing E.\u00a0coli ST131","volume":"74","author":"Kuroda","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl","key":"10.1016\/j.jiac.2015.04.006_bib8","first-page":"S42","article-title":"Epidemics of drug-resistant bacterial infections observed in infectious disease surveillance in Japan, 2001\u20132005","volume":"17","author":"Izumida","year":"2007","journal-title":"J\u00a0Epidemiol"},{"key":"10.1016\/j.jiac.2015.04.006_bib9","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1099\/jmm.0.049726-0","article-title":"Regional outbreak of CTX-M-2 b-lactamase-producing Proteus mirabilis in Japan","volume":"61","author":"Nakano","year":"2012","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.jiac.2015.04.006_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10156-012-0434-3","volume":"18","author":"Watanabe","year":"2012","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant b-lactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jiac.2015.04.006_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum b-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jiac.2015.04.006_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/138161213804070320","article-title":"b-Lactamase-mediated resistance: a biochemical, epidemiological and genetic overview","volume":"19","author":"Gutkind","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jiac.2015.04.006_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2012.04.013","article-title":"Prevalence of plasmid-mediated AmpC b-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum b-lactamase-producing E.\u00a0coli in Japan","volume":"40","author":"Matsumura","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2015.04.006_bib15","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum b-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of Carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jiac.2015.04.006_bib17","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-b-lactam b-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jiac.2015.04.006_bib18","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC b-lactamases","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime\u2013avibactam: a novel cephalosporin\/b-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2015.04.006_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.01198-10","article-title":"Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib21","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/AAC.01722-10","article-title":"Activity of NXL104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum b-lactamases and class C b-lactamases","volume":"55","author":"Lagace-Wiens","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In\u00a0vitro activity of the b-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib25","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jiac.2015.04.006_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcph.199","article-title":"Randomized, placebo-controlled study to assess the impact on QT\/QTc interval of supratherapeutic doses of ceftazidime\u2013avibactam or ceftaroline fosamil-avibactam","volume":"54","author":"Das","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jiac.2015.04.006_bib27","series-title":"Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers","author":"Edeki","year":"2013"},{"key":"10.1016\/j.jiac.2015.04.006_bib28","series-title":"Pharmacokinetic (PK) drug interaction study of ceftazidime\u2013avibactam (CAZ-AVI) and metronidazole (MTZ) in healthy volunteers","author":"Li","year":"2013"},{"key":"10.1016\/j.jiac.2015.04.006_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40261-015-0283-9","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies","volume":"35","author":"Merdjan","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jiac.2015.04.006_bib30","series-title":"Concentration of avibactam (AVI) and ceftazidime (CAZ) in plasma and epithelial lining fluid (ELF) in healthy volunteers","author":"Nicolau","year":"2013"},{"key":"10.1016\/j.jiac.2015.04.006_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.clinthera.2015.01.009","article-title":"Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers","volume":"37","author":"Tarral","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jiac.2015.04.006_bib32","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00641-09","article-title":"In\u00a0vitro activity of NXL104 in combination with b-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib33","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In\u00a0vitro antibacterial activity of the ceftazidime\u2013avibactam combination against Enterobacteriaceae, including strains with well-characterized beta-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib34","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/AAC.00080-14","article-title":"Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model","volume":"58","author":"Coleman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.04.006_bib35","author":"AVYCAZ Prescribing Information"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X15000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X15000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:53:57Z","timestamp":1761159237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X15000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1341321X15000902"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2015.04.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime\u2013avibactam in healthy Japanese volunteers","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2015.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}